DPP-4 inhibitors and their potential role in the management of type 2 diabetes
about
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitusPharmacological Modulators of Endoplasmic Reticulum Stress in Metabolic DiseasesLixisenatide as add-on therapy to basal insulinSitagliptin, An Anti-diabetic Drug, Suppresses Estrogen Deficiency-Induced OsteoporosisIn Vivo and Inhibits RANKL-Induced Osteoclast Formation and Bone Resorption In Vitro.Isolation of dipeptidyl peptidase IV (DP 4) isoforms from porcine kidney by preparative isoelectric focusing to improve crystallization.Pharmacophore Modeling and Molecular Docking Studies on Pinus roxburghii as a Target for Diabetes Mellitus.Effects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model.Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesHD047703, a New Promising Anti-Diabetic Drug Candidate: In Vivo Preclinical Studies.Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trialSaxagliptin for type 2 diabetesLinagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin.Synthesis and evaluation of [18F]exendin (9-39) as a potential biomarker to measure pancreatic β-cell mass.Pharmacological management of metabolic syndrome and its lipid complications.Effect of Glucagon-like Peptide-1 on the Differentiation of Adipose-derived Stem Cells into Osteoblasts and AdipocytesDevelopment of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoformsDiabetes mellitus: new challenges and innovative therapies.Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian SubjectsDipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells.Recent Advances in Effect-directed Enzyme Assays based on Thin-layer Chromatography.Type 2 diabetes mellitus: a review of current trendsEffects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.NPY1-36 and PYY1-36 activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies.Role of RACK1 in the differential proliferative effects of neuropeptide Y(1-36) and peptide YY(1-36) in SHR vs. WKY preglomerular vascular smooth muscle cells.Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.The pathophysiology of cardiovascular disease in diabetes mellitus and the future of therapy.Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) StudyNonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial.In vivo efficacy of HD0471953: a novel GPR119 agonist for the treatment of type 2 diabetes mellitus.Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.DPP-4 inhibitors in clinical practice.Spontaneous intracranial hemorrhage in a patient with Middle East respiratory syndrome corona virus.Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animalsIncretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
P2860
Q24243196-5E4247CF-094A-42B5-8340-1066AB707912Q26769765-5647FFE6-2D9F-4148-898C-305214D33CB5Q27007547-ABF2FCAF-9F96-4FCD-BA35-D7C34A8D3445Q33857358-00ABB027-FDC6-4FDA-AFAB-DACC3063501DQ33927989-EE33C207-309F-4596-97E8-20384B760914Q33996721-F9F68A48-051A-4174-8BF2-90E42ECB32F9Q34128774-90DA7517-8E80-49AD-B6D3-88EEA6747342Q34239784-0B1A364A-D945-4EAC-959A-108497FF073FQ34329204-BF840D96-17F5-4601-A3EB-40660DF6C97BQ34360545-4AC346E6-62C2-4988-A5FA-5F6E7D9A381AQ34610019-D5A152EC-76B3-4546-8E8A-840E7D7FF28AQ34620486-530172FD-A6AA-4D2E-AFB9-8ED478F736B6Q34637776-8EA57C44-33EF-444E-887D-7951EF34E798Q34718326-8FC321A4-FC74-4589-B752-F9BA8D3022F4Q34770205-86B5B997-E342-4EB9-AEDD-35116226AB23Q35794797-9A330CAB-FAAB-45AD-90E9-62B5EAA10EA1Q35832189-FA088F66-4620-4462-9BF5-68F9F5A4E624Q36033466-4505E644-F8C0-4AA6-A7FB-20DE92AD75E9Q36072219-2E2578D0-49A4-41D0-9310-BA71568F1C7FQ36117595-B18A5BED-1428-44A5-81EC-F8B3DBDD94F5Q36170755-6BCC405A-6E29-47BD-86D6-70DB73E46337Q36174657-39BE1849-C7B9-41EF-A472-C1E035F3DCD9Q36266184-72ABA70A-80AE-4DA4-B95E-A3C8867E5E4CQ36299039-D332F4F7-1356-4784-AB91-ACA3FCF729C8Q36315963-610BC06B-09E1-430A-8417-D207E82EB25CQ36339460-A7AF9900-5F13-4E02-9B2B-CCD627BE47C2Q36523427-A11C6C04-A793-4E2B-B93D-86062CF0E2EFQ36699796-D47C4AD1-373B-40BE-AA12-21DCF01D4EBEQ36764031-B0B5A04C-61BF-456B-9DE8-6CF463910DABQ36904452-837820AB-F5CA-4831-B864-6D26141EA1CCQ37188432-EC2D76C1-A6E5-4512-B5E6-1703C6459255Q37375539-05130517-87AB-45D3-B958-BCB84EF9B405Q37384190-A19AAE6D-B13D-4164-91CE-017675DE5741Q37412882-BCFA3659-FE9B-4C43-8FD9-E6C4507BE30CQ37603371-CAC29E49-6CD1-4429-BB4D-6B9B7A67C0D1Q37638984-D72A55FE-2E03-4AEA-B1E5-63DC176E0A3BQ37670743-FA838BB1-07B9-4056-A6F3-95BAF0A2A2D6Q37725539-EE163217-4ADD-4FA3-830A-5774A8E1152CQ37837059-6B77955F-2963-442B-8B23-C490FE7BE112Q37878396-1D1C0CE2-5318-4CB1-9630-583B0D6A9980
P2860
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
@ast
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
@en
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
@nl
type
label
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
@ast
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
@en
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
@nl
prefLabel
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
@ast
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
@en
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
@nl
P3181
P1476
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
@en
P2093
P304
P3181
P356
10.1111/J.1742-1241.2006.01178.X
P407
P577
2006-11-01T00:00:00Z